Prevnar 13
Blood & Organ Banks · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
CanadaWebsite
www.prevnar13.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Prevnar 13
PREVNAR 20 is a pneumococcal 20-valent conjugate vaccine designed to protect babies and children aged 2-18 years from invasive pneumococcal disease (IPD) caused by 20 different bacterial strains. It is specifically targeted at those with moderate to severe persistent conditions such as asthma, diabetes, and chronic heart disease. The vaccine is essential for building defenses against IPD and includes four crucial doses. PREVNAR 20 may also be available at no cost, and the company provides resources for insurance coverage and answers to common questions for parents.Explore more
Popular SearchesPrevnar 13SIC Code 28,283NAICS Code 32,325Show more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Prevnar 13 your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Prevnar 13 has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Prevnar 13
Check out if Prevnar 13 is spiking on competitors!
Earning: See what the market has to say on Prevnar 13 recently announced quarterly report
Product Launch: Get notified when Prevnar 13 launches new products
Funding: Get notified immidiatlly once Prevnar 13 has new funding data
Click to see if Prevnar 13 had a recent Job posting/layoffs
Prevnar 13, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Prevnar 13
Find more new buyers
Compare Similar Companies to Prevnar 13
Compare insights from companies similar to Prevnar 13, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Prevnar 13
<$5M
1-10
Private
-
-
N/A
Company Profile Activity
Activity Insights
Prevnar 13 is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Prevnar 13 is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Prevnar 13.
Prevnar 13 Tech Stack
A closer look at the technologies used by Prevnar 13
Top Blood & Organ Banks Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Prevnar 13
Sign Up For FreeTo access detailed company insights
PREVNAR 20 is a pneumococcal 20-valent conjugate vaccine designed to protect babies and children aged 2-18 years from invasive pneumococcal disease (IPD) caused by 20 different bacterial strains. It is specifically targeted at those with moderate to severe persistent conditions such as asthma, diabetes, and chronic heart disease. The vaccine is ess... Read More
